AGENNIX, INC.

Basic Information

AGENNIX, INC.
8 GREENWAY PLZ, STE 910
HOUSTON, TX, 77046 0892

Company Profile

n/a

Additional Details

Field Value
DUNS: 808956700
Hubzone Owned: Y
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Lactoferrin Enhances Growth and Reduces Nosocomial Infection in Preterm Infants

    Amount: $571,731.00

    DESCRIPTION (provided by applicant): This project aims to develop talactoferrin (TLF, recombinant human lactoferrin) as a therapeutic agent to treat prematurely born neonates. The treatment will be gi ...

    SBIR Phase II 2009 Department of Health and Human Services
  2. Lactoferrin Enhances Growth and Reduces Nosocomial Infection in Preterm Infants

    Amount: $557,320.00

    DESCRIPTION (provided by applicant): This project aims to develop talactoferrin (TLF, recombinant human lactoferrin) as a therapeutic agent to treat prematurely born neonates. The treatment will be gi ...

    SBIR Phase I 2008 Department of Health and Human Services
  3. Treatment of Sepsis with Talactoferrin

    Amount: $2,462,040.00

    DESCRIPTION (provided by applicant): Severe sepsis is a major cause of morbidity and mortality throughout the world. It is the leading cause of death in non-coronary intensive care units (ICUs) in the ...

    SBIR Phase II 2008 Department of Health and Human Services
  4. Treatment of Sepsis with Talactoferrin

    Amount: $570,399.00

    DESCRIPTION (provided by applicant): Severe sepsis is a major cause of morbidity and mortality throughout the world. It is the leading cause of death in non-coronary intensive care units (ICUs) in the ...

    SBIR Phase I 2007 Department of Health and Human Services
  5. Treatment of Sepsis using Recombinant Human Lactoferrin

    Amount: $130,595.00

    DESCRIPTION (provided by applicant): Severe sepsis is a major cause of mortality and morbidity in the US (Angus DC et al., 2001) with some 751,000 cases annually, costing on average over $22,000/case, ...

    SBIR Phase I 2006 Department of Health and Human Services
  6. Phase II Clinical Trial of Lactoferrin in Asthma

    Amount: $749,920.00

    DESCRIPTION (provided by applicant): The purpose of this research is to determine the efficacy of orally administered recombinant human lactoferrin (rhLF) in Phase II clinical trials in patients with ...

    SBIR Phase II 2005 Department of Health and Human Services
  7. Safety and efficacy of rh-Lactoferrin in Diabetic Ulcers

    Amount: $715,265.00

    DESCRIPTION (provided by applicant): Research Objectives: Determine the safety, pharmacokinetics, pharmacodynamics, and efficacy of topical recombinant human lactoferrin (rhLF) in promoting healing ...

    SBIR Phase II 2004 Department of Health and Human Services
  8. Recombinant human lactoferrin to treat oral mucositis

    Amount: $349,929.00

    DESCRIPTION: Oral mucositis is a major dose-limiting toxic effect of intensive cancer chemotherapy and radiotherapy. In addition to the morbidity directly caused by severe oral mucositis, it can cause ...

    SBIR Phase I 2004 Department of Health and Human Services
  9. Lactoferrin in Primate and Mouse Models of Asthma

    Amount: $99,925.00

    DESCRIPTION (provided by applicant): The purpose of this research is to extend work to determine the efficacy of orally administered recombinant human lactoferrin (rhLF) in an established primate mode ...

    SBIR Phase I 2004 Department of Health and Human Services
  10. Recombinant Lactoferrin and Necrotizing Enterocolitis

    Amount: $115,800.00

    DESCRIPTION (provided by applicant): This feasibility study is based on our hypothesis that recombinant human lactoferrin [rhLF] can prevent or reduce severity of necrotizing enterocolitis [NEC]. NEC ...

    STTR Phase I 2004 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government